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We previously demonstrated that prodynorphin (PDYN) haplotypes and single nucleotide 
polymorphism (SNP) rs2281285 are associated with alcohol dependence and the propensity to drink 
in negative emotional states, and recent studies suggest that PDYN gene effects on substance 
dependence risk may be sex-related. We examined sex-dependent associations of PDYN variation 
with alcohol dependence and related phenotypes, including negative craving, time until relapse 
after treatment and the length of sobriety episodes before seeking treatment, in discovery and 
validation cohorts of European ancestry. We found a significant haplotype-by-sex interaction 
(p  =  0.03), suggesting association with alcohol dependence in males (p = 1E-4) but not females. The 
rs2281285 G allele increased risk for alcohol dependence in males in the discovery cohort (OR = 1.49, 
p = 0.002), with a similar trend in the validation cohort (OR = 1.35, p = 0.086). However, rs2281285 
showed a trend towards association with increased negative craving in females in both the discovery 
(beta = 10.16, p = 0.045) and validation samples (OR = 7.11, p = 0.066). In the discovery cohort, 
rs2281285 was associated with time until relapse after treatment in females (HR = 1.72, p = 0.037); in 
the validation cohort, it was associated with increased length of sobriety episodes before treatment 
in males (beta = 13.49, p = 0.001). Our findings suggest that sex-dependent effects of PDYN variants 
in alcohol dependence are phenotype-specific.
Converging evidence from experimental studies and postmortem human brain research indicate that 
the dynorphin/kappa-opioid receptor system plays an important role in alcohol and drug dependence1–4. 
Genetic findings indicate that sequence variations in PDYN and OPRK1 genes—which encode dynor-
phins and the kappa-opioid receptor, respectively—are associated with risk for alcohol dependence5,6, as 
well as opioid and cocaine dependence7,8. We recently demonstrated that PDYN haplotypes are associated 
with increased risk for alcohol dependence and propensity to use alcohol in order to relieve negative 
emotions (negative craving)9. We also found that the minor G alleles of rs2281285 in the second intron 
and rs6132153 downstream of PDYN exhibited trends towards association with both phenotypes9. In a 
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separate study sample, we demonstrated that the rs2281285 G allele is also associated with drinking in 
order to avoid somatic or emotional discomfort associated with alcohol withdrawal10–another phenotype 
associated with negative craving11.
Negative (or ‘relief ’) craving is defined as the desire for drinking (craving) in the context of tension 
or negative emotions, in contrast to positive (or ‘reward’) craving defined as the desire for the rewarding 
properties of alcohol, or obsessive thoughts about drinking (obsessive or ‘temptation’ craving), concep-
tualized in a three-pathway psychobiological model11. According to this model, negative/relief craving 
reflects dysregulation in the glutamate/GABA balance in favor of excitation excess, while positive/reward 
craving reflects dysregulation in dopamine/opioid neurotransmission, and obsessive/temptation crav-
ing is attributed to dysregulation in serotonin neurotransmission11. The evolving understanding of the 
complexity of opioid neurotransmission and the role of dynorphin/kappa-opioid receptor signaling in 
negative emotions and addiction12,13 and our findings associating PDYN variation with negative craving 
and alcohol withdrawal9,10, indicate that biological underpinnings of each contextual subtype of craving 
requires further investigation.
Subtypes and patterns of manifestation of alcohol and substance dependence are also known to be 
sex-dependent. For example, research findings indicate higher rates of alcohol dependence in males14; 
however, females report tendency to drink in response to unpleasant emotions more often than males, and 
these associations are mediated by depression severity15. Our data indicate a stronger tendency towards 
heavy drinking in unpleasant emotional situations in female compared to male alcoholics16. Recently, 
it has been recognized that sexual dimorphism in disease may arise through evolutionary mechanisms 
(such as sexual selection and sexual antagonism)17, resulting in sex-dependent genetic architecture18,19; 
in fact, heritability estimates for alcohol dependence are higher in males than females, indicating that 
genetic risk may be sex-dependent14.
Importantly, experimental studies indicate sex-related differences in sensitivity to depressive-like 
effects of the kappa opioid receptor agonist20. Evidence also indicates that sequence variants within the 
PDYN gene modulate its expression and that effects on transcription differ by brain region, sex, and cell 
type21. Moreover, experimental data indicates that PDYN expression in brain and ovarian tissue is mod-
ulated by dihydrotestosterone and gonadal steroid hormones22,23, and that PDYN mRNA levels, as well 
as cocaine-induced behaviors, may be modulated by estrogen and progesterone24. Therefore, it is possible 
that effects of PDYN variants on development of alcoholism and related phenotypes may also differ in 
males and females, resulting in SNP by sex interactions and sex-dependent genetic effects.
In fact, a sex-specific association between the C allele of downstream PDYN variant rs1022563 and 
risk of heroin dependence has been reported25,26. According to the 1000 Genomes Project Phase 1 CEU 
data, in populations of European ancestry, rs1022563 is in high linkage disequilibrium (LD, R2 = 0.81) 
with rs2281285, and is also in perfect LD (R2 = 1) with rs6132153--SNPs which we found to be associated 
with alcohol dependence and negative craving in European American subjects9. Therefore, it is possible 
that these PDYN variants exhibit related sex-dependent effects across substance-dependence and related 
traits.
To test these hypotheses, we re-analyzed our previously reported data by examining SNP-by-sex 
interaction effects on alcohol dependence and negative craving. We also conducted additional analyses 
focused on related phenotypes, including time to relapse after treatment and the length of sobriety epi-
sodes before seeking treatment.
Methods
Discovery Sample. This work was approved by the Institutional Review Board of the Mayo Clinic, 
Rochester, Minnesota and was conducted according to the Code of Ethics of the World Medical Association 
(Declaration of Helsinki). All participants signed informed consent and gave permission for the use 
of their information in future research of alcohol dependence and related phenotypes. Characteristics 
of the samples and genotyping procedures have been described previously9,27. In brief, the discovery 
cohort consisted of 816 alcohol-dependent cases and 1248 controls recruited from alcohol dependent 
subjects and non-alcohol dependent controls treated in programs affiliated with Mayo Clinic, Rochester, 
Minnesota9. The Illumina GoldenGate SNP assay was used for genotyping in alcohol dependent subjects 
(cases), and included 13 PDYN variants (chosen to match the 13 PDYN variants previously genotyped 
in controls) and 43 ancestry informative markers28 used to verify self-reported race. The genotyping 
data for control subjects was retrieved from a previously published genome wide association study using 
the Illumina 660 genome-wide SNP array29. While potential control subjects with a history of alcohol 
dependence were excluded, controls were not required to have a history of exposure to alcohol. Controls 
were not matched to cases on age and sex, and were older and included more females9.
Because PDYN has undergone positive selection, minor allele frequencies for PDYN variants differ 
substantially across human subpopulations30, potentially increasing the possibility for spurious asso-
ciations due to population stratification. To avoid this risk, analyses were restricted to subjects with 
European ancestry, which were verified with the use of ancestry informative markers. Both discovery 
and validation cases were recruited from subjects actively enrolled in alcohol treatment programs (see 
Supplementary Materials for a description of the treatment programs). Clinical and demographic charac-
teristics of the alcohol dependent subjects included in the discovery and validation cohorts are described 
below and summarized in Table 1.
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In the discovery cohort, presence of alcohol dependence was determined in a clinical assessment by 
board certified addiction psychiatrists and defined based on DSM-IV-TR criteria31. Negative craving 
was measured by the negative sub-scale of the Inventory of Drug Taking Situations (IDTS)32. Relapse 
after treatment was defined as a return to any alcohol use following completion of treatment. Time 
until relapse was measured in the 12 month period following standard treatment. Relapse/sobriety data 
are collected as a part of clinical follow up at 3, 6, 9 and 12 month intervals after completing standard 
treatment.
Statistical Analysis. Our previous study indicated that the effects of PDYN on alcohol dependence 
were driven by rs22812859, so this variant was the primary focus of analysis. In the discovery cohort, 
we performed single SNP association tests for the previously reported rs2281285 variant. We assumed 
additive genetic effects, coding SNP genotypes as the number of copies of the minor allele (0–1–2). We 
evaluated sex-related effects on risk for alcohol dependence of rs2281285 by examining a SNP-by-sex 
interaction under a logistic regression model, adjusted for age and sex. Similarly, we examined the 
SNP-by-sex interaction of rs2281285 on negative craving using linear regression (adjusted for age and 
sex) in a subsample of N = 196 cases with available IDTS data. In addition to phenotypes investigated in 
our previous publications, we also examined the SNP-by-sex effects of rs2281285 on time until relapse (in 
months) in a subset of N = 202 case subjects with 12 months of follow-up data after treatment using Cox 
proportional hazards regression (adjusted for age and sex). Along with tests of SNP-by-sex interaction, 
analyses were also conducted adjusted for age and sex (without interaction), as well as adjusted for age 
and stratified by sex. Because the studied phenotypes of interest are highly correlated (and therefore can-
not be considered independent tests), no standard multiple testing correction was appropriate; reported 
p-values are uncorrected. Instead, we used validation in the independent sample (see below) as a way 
to determine robustness of association findings. All statistical analysis was performed in R Statistical 
Software, version 2.14.0 (http://www.r-project.org).
Sensitivity Analyses. As sensitivity analyses, the single SNP analyses of rs2281285 were repeated 
with the variant rs6132153, which is strongly linked (R2 = 0.82 in controls); this variant is in complete 
LD with another variant previously associated with opioid dependence25. In the discovery cohort, we 
also examined previously identified haplotypes9 as sensitivity analyses, because haplotype analyses may 
be more powerful if an un-genotyped marker in linkage disequilibrium (LD) with rs2281285 is actually 
causal. Association tests of haplotype-by-sex interaction were adjusted for age and sex. Additionally, 
haplotype association tests were also performed adjusted for age and stratified by sex. We examined a 
previously identified PDYN gene-spanning haplotype (rs6045868-rs2235751-rs2281285) associated with 
alcohol dependence9 using logistic regression. Similarly, we examined the haplotype-by-sex interaction of 
a previously identified PDYN haplotype (rs6045784-rs910080-rs2235751-rs2281285)9 on negative craving 
using linear regression, and time until relapse using Cox proportional hazards regression. Haplotype asso-
ciation tests were performed using the score statistic proposed by Schaid et al.33, and empirically derived 
p-values are reported for the global test (4 degrees of freedom for the three SNP haplotype, and 5 degrees 







Age at admission (mean ± SD) 49.1 ± 12.1 43.5 ± 10.4 <0.0001
Sex (N and % male) 554 (67.9%) 347 (74.3%) 0.018
Average drinks/day at admission (mean ± SD) 8.4 ± 6.4 14.1 ± 8.5 <0.0001
Number of subjects investigated for each phenotype 
Alcohol dependence (cases/controls) 816/1248 467/431
Negative craving 196 417
 IDTS negative subscale (mean ± SD) 47.9 ± 21.0 N/M
  SSAGA question: Drinking to avoid emotional 
and physical symptoms of withdrawal (N and %) N/M 304 (72.9%)
 Return to drinking 202 409
 Relapse after treatment (N and %) 92 (45.5) N/M
  Maximum length sobriety in months 
(mean ± SD) N/M 22.4 ± 47.9
Table 1.  Demographic characteristics of the alcohol dependent cases and description of investigated 
phenotypes. *Demographic data are presented for alcohol dependent subjects only. Demographic data of 
controls are presented in previous publications9,10. N/M, not measured.
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and all haplotype analyses were performed using the R package ‘haplo.stats’ (http://cran.r-project.org/
web/packages/haplo.stats/). As the haplotype and analyses and analyses of rs6132153 are highly corre-
lated with the analyses of rs2281285, no additional multiple testing correction was applied.
Validation Sample. The validation cohort has been described in detail in a previous publication27. In 
brief, patients 18 years and older were consecutively recruited from an inpatient addiction treatment unit 
of the Department of Psychiatry, Ludwig-Maximilians University, Munich, Germany (see Supplementary 
Material). All study subjects met DSM IV criteria for alcohol dependence and were assessed with the 
Semi-Structured Interview for the Assessment on the Genetics of Alcoholism (SSAGA)34,35. All partici-
pants provided written informed consent approved by the ethical committee of the Ludwig-Maximilians 
University. Collected DNA samples were genotyped for rs2281285 only using a TaqMan® SNP Genotyping 
Assay in 467 alcohol dependent subjects and 431 controls, as described in our previous publication9.
In our previous publications, we examined the effects of rs2281285 on alcohol dependence and neg-
ative craving using this sample9,10, although sex-specific effects were not explored. In the present study, 
we used the validation cohort to examine the sex-dependent effects of rs2281285 on alcohol dependence 
using logistic regression, adjusted for age. The same measures of negative craving and time to return to 
drinking used in the discovery sample were not available in the validation sample, limiting the ability 
for direct replication; however, available measures assessing similar constructs were utilized to validate 
the findings of the discovery cohort. Specifically, because the IDTS assessment was not performed in 
this cohort, negative craving was instead assessed with a binary SSAGA item asking if the patient ever 
ingested alcohol to avoid unwanted emotional or somatic discomfort10; sex-specific effects of rs2281285 
were assessed with logistic regression, adjusted for age. Furthermore, data on time until relapse after 
treatment for alcohol dependence was not available in this sample. Therefore, a related variable of length 
of sobriety before seeking treatment was utilized to assess association with rs2281285 using age-adjusted 
linear regression. The choice of this variable was based on an assumption that vulnerability to negative 
craving associated with PDYN variation may cause earlier return to drinking at any time, not just after 
treatment.
Results
Descriptive Statistics. Description of demographic characteristics of the study cohorts and inves-
tigated alcoholism-related phenotypes are presented in Table  1. Both discovery and validation cohorts 
were recruited from subjects enrolled in treatment programs and included more males then females. 
However, the validation cohort was younger (p < 0.0001), had heavier alcohol consumption (p < 0.0001), 
and a higher percentage of males (p = 0.018); analyses were adjusted for age and sex in both sample 
sets, but differences in data collection methods prohibited adjustment for consumption in the discovery 
sample. The discovery cohort had a larger sample size of cases (N = 816) and controls (N = 1248) to 
test associations between PDYN variants and alcohol dependence compared to the validation cohort 
(N = 467 and 431, respectively). However, smaller numbers of participants in the discovery cohort were 
assessed with the negative subscale of IDTS (N = 196) and had available post-treatment relapse data 
(N = 202). In the validation cohort, response to the SSAGA question about drinking to avoid emotional/
physical symptoms of withdrawal (yes/no) and data about maximum length of sobriety before treatment 
were available for most subjects (N = 417 and 409, respectively).
Alcohol Dependence. The SNP-by-sex interaction effect of rs2281285 on alcohol dependence did 
not reach a statistically significant level but showed a trend towards association in the discovery cohort 
(p = 0.099), indicating that the effect of rs2281285 on risk for alcohol dependence may depend on sex. 
Subsequent stratified analyses examining the SNP effect separately in males and females yielded consist-
ent results in the discovery and validation cohorts. As shown in Tables 2 and 3, we observed a stronger 
association between risk for alcohol dependence and the rs2281285 G allele in males in both the discov-
ery (OR = 1.49, p = 0.002) and the validation cohort (OR = 1.35, p = 0.08), but no significant association 
in females.
Negative Craving. Conversely, sex-stratified analyses of rs2281285 on negative craving showed an 
association in females but not males (Tables 2 and 3). In females, the G allele of rs2281285 was associated 
with increased negative craving in the discovery sample (beta = 10.16, p = 0.05; Table  2), and trended 
towards association with avoidance of unwanted emotional and somatic discomfort in the validation 
sample (OR = 7.11, p = 0.07; Table 3).
Return to Drinking. Similarly, the rs2281285 G allele was associated with increased risk of 
post-treatment relapse (OR = 1.42, p = 0.048) in the discovery cohort (Table  2), where the associa-
tion is driven by females (HR = 1.72, p = 0.037) but not males. In the validation cohort (Table  3), the 
minor rs2281285 G allele was associated with an increased length of sobriety of 10 months on average 
(p = 0.02), but the effect is driven by males (beta = 13.5, p = 0.001).
Sensitivity Analyses. Single SNP results for rs6132153 were similar to those for rs2281285 for 
all phenotypes in the discovery cohort (Supplemental Table  1). Additionally, we found a statistically 
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significant haplotype-by-sex interaction effect on alcohol dependence in the discovery cohort (p = 0.03). 
In a sex-stratified analysis (Supplemental Table  2), the rs6045868-rs2235751-rs2281285 haplotype was 
associated with alcohol dependence in males (p = 1E-4) but not females. There was no significant 
PDYN gene-spanning haplotype-by-sex interaction effect on negative craving or time until relapse after 
treatment.
Discussion
Results presented here demonstrate that our previously reported findings of association between PDYN 
SNPs and haplotypes and alcohol dependence may be sex-related, and importantly, the sex-dependent 
effects are also trait (phenotype)-specific. A significant haplotype-by-sex interaction was observed for 
alcohol dependence, and stratified analyses indicated that the effect of the PDYN-spanning haplotype 
was present in males only. However, the SNP-by-sex interaction for rs2281285 was only marginally sig-
nificant, indicating that perhaps rs2281285 is not the causal variant, but rather is in LD with a causal 
variant (or multiple variants) that is also tagged by the PDYN-spanning haplotype. Similarly to the results 
of the haplotype analysis, the effect of the minor G allele of rs2281285 was stronger in males in both 
discovery and validation cohort analyses, and the male-specific effect observed in the discovery cohort 
was statistically significant. This effect was consistent in the direction and effect size in the validation 
cohort, where, despite smaller sample size, we also observed a trend for association of the rs2281285 
G allele with increased risk for alcohol dependence in male but not in female alcoholics. Moreover, in 
Phenotype Sex N case/control MAF (case/control) Effect Size* 95% CI P-value
Alcohol Dependence
Both†† 816/1248 0.173/0.142 1.30 (1.07, 1.58) 0.008
Male† 554/603 0.171/0.129 1.49 (1.15, 1.93) 0.002
Female† 262/645 0.176/0.154 1.07 (0.79, 1.45) 0.684
Negative Craving
Both†† 196 0.157 6.95 (1.55, 12.34) 0.012
Male† 129 0.146 5.14 (-1.34, 11.61) 0.123
Female† 67 0.179 10.16 (0.44, 19.88) 0.045
Time Until Relapse
Both†† 202 0.178 1.42 (1.00, 2.00) 0.048
Male† 134 0.157 1.17 (0.73, 1.89) 0.502
Female† 68 0.221 1.72 (1.03, 2.85) 0.037
Table 2. Association of PDYN variant rs2281285 with alcohol dependence, negative craving, and time 
until relapse in the discovery (Mayo) sample, stratified by sex. *Type of effect size measure is phenotype-
specific: alcohol dependence = odds ratio, negative craving = beta (unstandardized, ITDS 0-100 point scale), 
time until relapse = hazard ratio. Statistically significant associations (p < 0.05) are presented as bold and 
underlined; trend for association values (p < 0.1) are underlined. †Analyses were adjusted for age. ††Analyses 
were adjusted for age and sex.
Phenotype Sex N case/control MAF case/control
Effect 
size* 95% CI P-value
Alcohol Dependence
Both†† 467/431 0.163/0.148 1.18 (0.91, 1.54) 0.223
Male† 347/224 0.166/0.129 1.35 (0.96, 1.91) 0.086
Female† 120/207 0.154/0.169 0.94 (0.61, 1.47) 0.808
Drinking to avoid emotional/
physical discomfort
Both†† 417 0.173 2.29 (1.08, 4.85) 0.030
Male† 311 0.174 1.79 (0.80, 4.01) 0.158
Female† 102 0.175 7.11 (0.88, 57.40) 0.066
Longest period of sobriety 
any time before treatment
Both†† 409 0.172 10.064 (1.55, 18.57) 0.0209
Male† 306 0.175 13.487 (5.18, 21.79) 0.0016
Female† 103 0.171 –2.482 (–26.55, 21.59) 0.8403
Table 3.  Association of PDYN variant rs2281285 with alcohol dependence, drinking to avoid emotional 
discomfort, and length of sobriety in the validation (German) samples, stratified by sex. *Effect 
size measure is dependent on phenotype; alcohol dependence = odds ratio, drinking to avoid emotion 
discomfort = odds ratio, length of sobriety = beta (months). Statistically significant associations (p < 0.05) 
are presented as bold and underlined; trend for association values (p < 0.1) are underlined. †Analyses were 
adjusted for age. ††Analyses were adjusted for age and sex.
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sex-specific analyses of the effect of rs2281285 on negative craving, we observed a female-specific trend 
for association between the rs2281285 minor G allele and increased negative craving in both the discov-
ery and validation cohorts. Similarly, the minor rs2281285 G allele was associated with increased risk 
of relapse in female subjects in the discovery cohort, while in the validation cohort this same allele was 
associated with increased length of sobriety before treatment in male alcoholics.
Notably, the genetic effects detected here have not been previously implicated in genome-wide asso-
ciation studies of alcohol dependence36–40. Many of these studies did not investigate SNP-sex interactions 
or perform sex-stratified analyses; and for prior studies that examined sex strata (or included males only), 
sample sizes were small. Our results demonstrating sex-specific genetic effects on alcohol related traits 
suggest that effects for some SNPs may be larger in one sex; by analyzing males and females together, 
the effects would be reduced and may not be detected. In light of evolutionary mechanisms underlying 
sex differences in disease risk18, it is likely that interactions between genetic variants and sex exist, and 
ignoring such interactions in analyses can prevent detection of certain genetic effects41.
The findings of this study are intriguing, as the minor alleles of the PDYN SNPs rs2281285 and 
rs6132153 seem to have different effects on risk for alcohol dependence, negative craving and the length 
of sobriety before and after treatment for males and females. Specifically, the minor G alleles of these 
genetic variants convey increased risk for alcohol dependence in males, while increasing vulnerability 
to negative craving and post-treatment relapse in alcohol dependent females. One possible explanation 
for these findings is that the above mentioned genetic variants are associated with an intermediate phe-
notype, which is more common in alcoholic males compared to non-alcoholic males, and even more 
common in alcoholic females. Increased stress vulnerability as well as comorbidity of alcohol dependence 
with depression and/or anxiety are among potential candidates for such an intermediate phenotype(s). In 
fact, clinical and epidemiological studies indicate that comorbid depression or anxiety are more common 
in alcoholics compared to the general population, and are also more common in alcoholic females than 
males42–44, while alcohol consumption in the context of negative emotional states (negative craving) is 
also known to be associated with female sex15,16.
Importantly, the presence of comorbid mood and anxiety disorders in alcohol dependent subjects 
is reported among empirically described subtypes of alcohol dependence, which are also characterized 
by persistence of symptoms, treatment seeking and worse mental health status45,46. Moreover, evidence 
indicates that comorbidity of alcohol dependence with mood and anxiety disorders appears to be attrib-
utable to factors shared among these disorders47. Although speculative at this point, it is possible that the 
sex-related effects of the PDYN variants reported here are narrowing in on the genetic underpinnings of 
these particular subtypes of alcohol dependence. Similarly, other traits relevant to alcohol dependence 
that may differ between males and females should also be considered, as additional factors may be 
involved in higher-order (perhaps endophenotypic) interactions with SNP and sex effects on alcohol 
dependence, and may define important sex-associated subtypes. For example, negative craving is asso-
ciated with length of time abstinent from drinking48, and our data suggests that both sex and PDYN 
variants may modify these relationships. These hypotheses regarding the role of comorbidities, and how 
they may have impacted the observed associations, should be investigated in the future studies.
Several limitations to the current study need to be acknowledged. First, sample size limited power 
to detect gene-sex interactions and sex-specific effects. Fewer female subjects in both the discovery and 
validation cohorts resulted in lower power for female-specific compared to male-specific analyses, and 
because the discovery and validation samples were selected with alcohol dependence as the primary 
phenotype of interest, sample sizes and power to detect associations with the secondary case-only phe-
notypes were reduced. Furthermore, the validation sample was smaller than the discovery sample with 
respect to the primary phenotype, which also limited power.
Second, the controls in the discovery cohort were previously ascertained from a sample of control 
subjects representing the general population. This has become a common strategy in study of genetic epi-
demiology49. However, because of this, cases and controls were genotyped separately (although subjects 
genotyped in both sets were 100% concordant) and controls were not matched to cases on either age or 
sex. To mitigate this difference, analyses were adjusted for age and sex to eliminate potential biases due 
to these factors. Although control subjects with a history of alcohol dependence were excluded, controls 
were not required to have a history of exposure to alcohol. We do not expect this approach to induce 
an ascertainment bias, but perhaps further reduce power, because the control population may include 
subjects with high genetic risk who may have developed alcohol dependence after exposure50.
Third, because the phenotypes investigated here are highly correlated, the analyses we conducted were 
highly dependent. Therefore, multiple testing correction methods (e.g. Bonferroni correction or false dis-
covery rate methods) commonly used to correct for the number of independent tests were not utilized. 
In the absence of such a correction, we relied on validation in the independent sample to support the 
robustness of our findings. Due to the large dependence among tests, the findings reported here likely 
represent a single underlying phenomenon, and subsequent studies will be necessary to gain a better 
understanding of these observations.
Finally, the differences between the discovery and validation samples should also be noted. Key char-
acteristics such as age, sex, and alcohol consumption levels differed between the study samples, suggest-
ing that both samples may represent different populations of alcoholics. Moreover, identical measures for 
negative craving and return to drinking were not available in the validation cohort, limiting our ability to 
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directly replicate the findings in the discovery cohort. Yet, consistent findings acquired in samples differ-
ing in those characteristics and with different measured assessments of the same underlying phenotypes 
can be interpreted as validation, rather than direct replication of our findings; this is true particularly 
regarding the phenotypes of alcohol dependence and negative craving. Regarding return to drinking, 
length of sobriety before treatment was chosen as a surrogate measure for time until relapse, under the 
assumption that PDYN variation may be associated with earlier return to drinking at any time. It seemed 
reasonable to assume that these phenotypes would be correlated, although, in fact, these phenotypes 
are targeting events (sobriety) before and after treatment, which may potentially be driven by different 
mechanisms. Therefore the differences in association found between the rs2281285 G allele and length 
of sobriety in male and female alcoholics before and after treatment may be indicative of a different 
underlying biology. Further studies are needed to investigate whether these results are due to the fact 
the phenotypes are distinct, or caused by differences in clinical characteristics between the discovery and 
validation samples (e.g. differences in levels of alcohol consumption), or simply due to false positive asso-
ciations. However, despite the differences in study samples and the smaller size of the validation sample, 
we were able to validate the magnitude and direction of many of the discovered associations regarding 
the alcohol dependence and negative craving phenotypes. This consistency of results across samples from 
populations with differing clinical characteristics highlights the robustness of these findings.
In conclusion, our findings support growing evidence that the dynorphin-kappa-opioid system is 
a critical component linking negative emotions with substance dependence51–53. Our findings expend 
contemporary knowledge by demonstrating that PDYN effects on alcohol use disorders differ between 
males and females, and this pattern of this difference appears to depend on phenotype. Although the 
exact mechanisms of the reported associations are yet unclear, the results of this study suggest the fol-
lowing directions for future research. First, a search for intermediate phenotypes associated with alcohol 
dependence subtypes and relevant comorbidities are needed, using meta-analyses and/or combined data 
sets of subjects with genome wide data to allow increased sample size. Second, PDYN sequencing in 
alcoholics with the proper clinical assessments and treatment outcome data will provide more compre-
hensive coverage of potentially causal variants and allow testing for association with the above mentioned 
phenotypes. Last but not least, functional analyses of biological pathways and potential cis and trans 
regulatory mechanisms involving PDYN brain expression are necessary to disentangle the meaning and 
examine potential causal mechanisms of the differential sex association.
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